Monoamine Oxidase Inhibitors in Parkinson’s Disease

1989 ◽  
pp. 411-431 ◽  
Author(s):  
M. Sandler ◽  
V. Glover
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitors

The evolving role of monoamine oxidase inhibitors in the treatment of Parkinson's disease

Neurology ◽  
2004 ◽  
Vol 63 (Issue 7, Supplement 2) ◽  
pp. S1-S1
Author(s):  
W. C. Koller ◽  
M. B. Stern ◽  
R. Watts
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitors

scholarly journals A szelektív monoaminoxidáz-B-gátlók helye a Parkinson-kór kezelési stratégiájában a marosvásárhelyi ideggyógyászati klinikák gyakorlatában

2017 ◽  
Vol 158 (51) ◽  
pp. 2023-2028
Author(s):  
József Attila Szász ◽  
Viorelia Constantin ◽  
Péter Alpár Fazakas ◽  
Eszter Blényesi ◽  
Levente Gábor Grieb ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Dopamine Agonists ◽  
Disease Duration ◽  
Monoamine Oxidase Inhibitors ◽  
Monoamine Oxidase B ◽  
Advanced Stages ◽  
Therapeutic Recommendations

Abstract: Introduction: Selective monoamine oxidase B inhibitors have an accurate place in therapeutical strategy of Parkinsons’s disease. In the early stages of the disease, especially in younger patients with milder symptoms, the introduction of levodopa substitution could be efficacious in delaying; in advanced stages they are mainly used to treat motor complications, as an adjunct to levodopa. Aim: The evaluation of therapeutical strategies used in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital in order to define the role of monoamine oxidase B inhibitors. Method: This retrospective study includes all records of patients with Parkinson’s disease hospitalized between 1 January 2003 and 31 December 2016. From the 2194 reports we used data focusing on the therapeutic recommendations. Regarding disease duration, we divided the patients in two groups: less than or equal to 5 years and more than 5 years. Results: From the 1183 patients in first group, 243 received monoamine oxidase inhibitors: 12 as monotherapy, 52 together with dopamine agonists, in 61 cases combined with levodopa. In 118 cases monoamine oxidase inhibitors were combined with levodopa and dopamine agonists. From 582 cases whith Parkinson’s disease for more than 5 years, 195 received monoamine oxidase B inhibitors (selegiline: 10 cases, rasagiline: 185 cases). In 429 cases we did not find accurate data regarding disease duration (selegiline: 5 cases, rasagiline: 93 cases). Conclusion: The use of monoamine oxidase B inhibitors was similar to those found in literature. The treating physicians should utilise more confidently the available therapeutical combinations. Orv Hetil. 2017; 158(51): 2023–2028.

A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease

Neurology ◽  
2004 ◽  
Vol 63 (Issue 7, Supplement 2) ◽  
pp. S32-S35 ◽  
Author(s):  
M. B.H. Youdim ◽  
P. F. Riederer
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document